ArticleTranslational vision science & technology2026
Preclinical Safety and Feasibility Study of Line-Field Confocal Optical Coherence Tomography for Ophthalmology Applications.
Article in Translational vision science & technology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: The purpose of this study was to demonstrate the first use of a commercially available, CE-marked line-field confocal optical coherence tomography (LC-OCT) in ophthalmology and assess its safety and feasibility for ocular imaging in rabbits, focusing on phototoxicity and tissue integrity. Methods: Five 14-week-old New Zealand White rabbits underwent corneal imaging using the DeepLive device (DAMAE Medical, Paris, France), originally developed for dermatologic applications. Imaging sessions lasted 5 to 10 minutes per eye, using illumination at a center wavelength of 820 nm and a power of 13.2 mW. Safety was evaluated in silico according to International Electrotechnical Commission (IEC) 60825-1 standards and in vivo through clinical assessments including slit-lamp examination, retinal imaging, and intraocular pressure (IOP) measurements at baseline, immediately after imaging, and on days 7 and 14. Histological analysis was performed day 14. Results: LC-OCT provided high-resolution three-dimensional imaging of the cornea (1.2 × 0.5 × 0.5 mm) and two-dimensional views of corneal layers, conjunctiva, and the nictitating membrane, revealing cellular details. In silico analysis confirmed that laser exposure remained below IEC safety limits. In vivo evaluations showed no corneal opacity, neovascularization, inflammation, or retinal alterations at any time point. Lens transparency remained normal (Lens Opacities Classification System [LOCS] III grade = 0), and IOP showed no treatment-related differences (P = 0.6713). Histology confirmed preservation of corneal and retinal structures. Conclusions: Ophthalmologic use of CE-marked LC-OCT demonstrated safe, effective imaging in rabbits without phototoxicity, supporting its potential for clinical ophthalmic applications. Translational Relevance: These findings provide preclinical safety evidence supporting LC-OCT as a noninvasive, high-resolution imaging modality for future clinical ophthalmology applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.